Abstract. The spread of chloroquine-resistant Plasmodium vivax from Papua New Guinea and Indonesia poses a serious health threat to areas of Southeast Asia where this species of malaria parasite is endemic. A strain of P. vivax from Indonesia was adapted to develop in splenectomized Aotus lemurinus griseimembra, Aotus vociferans, Aotus nancymai, and Saimiri boliviensis monkeys. Transmission to splenectomized Saimiri monkeys was obtained via sporozoites. Chemotherapeutic studies indicated that the strain was resistant to chloroquine and amodiaquine while sensitive to mefloquine. Infections of chloroquine-resistant P. vivax in New World monkeys should be useful for the development of alternative treatments.
INTRODUCTION
In recent years, resistance of Plasmodium vivax to treatment with chloroquine has been reportedly widespread in Papua New Guinea and Indonesia, as well as elsewhere in restricted areas of Oceania and Southeast Asia. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Because of this, attempts are being made to establish isolates of these parasites to New World monkeys for chemotherapeutic, molecular, and immunologic study. The first such isolate, the AMRU-1 strain from Papua New Guinea, was established in Aotus monkeys and shown to be resistant to treatment with 30 mg chloroquine, a dosage routinely effective for treatment of sensitive strains of the parasite. 1 Additional studies resulted in the adaptation of the AMRU-1 strain to different species of Aotus and to Saimiri boliviensis monkeys. 13 Isolation of additional strains of this parasite should allow for the testing of alternative treatments and the development of molecular tests to determine the distribution and spread of these parasites. Until techniques are developed for routine in vitro culture of different strains of P. vivax and methods for in vitro drug testing become available, isolation and adaptation of these parasites to New World monkeys will be critical for the characterization of these strains and the identification of alternative treatments. Such was the case with drug-resistant Plasmodium falciparum before its adaptation to routine culture. 15 Following extensive reports of chloroquine resistance in Indonesia, 3, [5] [6] [7] [8] [9] [10] [11] [12] attempts were made to establish an endemic strain of P. vivax using frozen blood samples. During a treatment efficacy study being conducted in Indonesia in 1994, numerous samples were collected and stored frozen. In late 1996, some of these samples were shipped to the Centers for Disease Control and Prevention (CDC) in Chamblee, Georgia, where they were thawed, pooled, and injected into New World monkeys. Initially, single samples from individuals with high density parasite counts were injected into 8 splenectomized Aotus vociferans or Aotus lemurinus griseimembra monkeys; daily blood film examination for 60 days failed to detect any parasitemia. It was then decided to pool those remaining samples with the highest levels of parasitemia, regardless of their response to treatment. Eight additional splenectomized monkeys were injected with pools of samples from 4 or 5 different patients. One infection was induced.
Reported here is a description of our initial studies on the adaptation of one line of P. vivax (Indonesia XIX) derived from one such pool of samples to Aotus and Saimiri monkeys, and its response to treatment with chloroquine, amodiaquine, and mefloquine.
MATERIALS AND METHODS

Animals.
Aotus vociferans and Aotus nancymai monkeys from Peru, and laboratory-born Aotus lemurinus griseimembra, and Saimiri boliviensis monkeys were used in the study. All animals were quarantined upon arrival at the facility for at least 1 month, weighed, and tested by skin test for tuberculosis. Parasitologic examination indicated that the animals were free of plasmodial infection. Many of the animals had been previously used in other malaria-related studies and subsequently cured of their infections. Protocols were reviewed and approved by the Centers for Disease Control and Prevention Institutional Animal Care and Use Committee, in accordance with procedures described in the U.S. Public Health Service Policy, 1986. Daily observations of the animals' behavior, appetite, stool, and condition were recorded. Monkeys were weighed weekly. All were treated as medical conditions arose by an attending veterinarian. All observations, parasite counts, and the results of laboratory tests were recorded on a daily basis and entered into a computerized database.
Animals were housed singly or doubly to avoid injuries caused by fighting with cagemates. Space recommendations for laboratory animals were followed as set forth in the Guide for the Care and Use of Laboratory Animals, NIH. All monkeys were fed a diet that has been proven to provide adequate nutrition and calories in captive Aotus and Saimiri monkeys used in malaria-related research. Feed was free of contaminants and freshly prepared. Animals were handled as little as possible. They were administered 0.1 cc ketamine hydrochloride intramuscularly for sedation when given a physical examination, had blood drawn, and were weighed. On days when only blood was drawn or the animals were weighed only, anesthesia was not given. All procedures in- volving the animals were under the direction of the resident clinical veterinarian.
Surgery. Animals were splenectomized to reduce or eliminate any residual immunity that might effect their response to infection with this strain of P. vivax. All surgeries were performed in an AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care, International, Inc.) approved surgical suite appropriate for aseptic surgery.
Parasite monitoring. Animals were inoculated intravenously with heparinized parasitized erythrocytes, either collected fresh from other infected animals or with parasites that had been stored frozen over liquid N 2 . In seven instances, monkeys were injected with sporozoites, either dissected from infected salivary glands or via mosquito bites. Mosquitoes were routinely allowed to feed on tranquilized infected animals during periods of ascending or high density parasitemia. Mosquitoes were subsequently dissected beginning 7 days after feeding to determine the presence of oocysts. Mosquitoes from infected lots were dissected beginning 14 days after feeding to determine the presence of sporozoites in the salivary glands. Beginning 1 day after injection of parasitized erythrocytes or 14 days after sporozoite inoculation, thick and thin blood films were collected daily and stained with Giemsa by the method of Earle and Perez. 14 Parasite counts were recorded per L of blood.
Treatments. Once the parasitemia was established, individual animals were selected for treatment with chloroquine, amodiaquine, or mefloquine. Animals ranged in weight from 600 to 1,000 grams. Treatment was given by oral intubation and was not varied based on the weight of the animal. Chloroquine (10, 20, or 30 mg base) was administered over 1, 2, or 3 days. Amodiaquine (30 mg base) was given over 2 days. Treatment failures were subsequently cured by treatment with mefloquine. Following treatment, animals were followed for at least 60 days by daily thick blood film examination to confirm cure of their infections.
RESULTS
The samples were collected from the Arso PIR IV village in northeastern Irian Jaya (Indonesian New Guinea) in 1994. 10 This village is located 50 km from the Pacific Ocean and about 15 km from the international border with Papua New Guinea. Residents were transmigrants from Java. Samples (ARSO VB-6, 15, 16, 17, and 19) were thawed, pooled, and injected into A. l. griseimembra monkey AI-4045. Infections from an 8-year-old girl (VB-6) and a 26-year-old woman (VB-15) had been shown in clinical studies to be chloroquine resistant, whereas infections from an 11-yearold boy (VB-16), a 35-year-old man (VB-17), and a 25-yearold woman (VB-19) had been shown to be chloroquine sensitive. Parasites were first seen on the peripheral blood film of monkey AI-4045 41 days after injection. Parasites were subsequently maintained either by linear passage into additional Aotus or Saimiri monkeys or stored frozen over liquid N 2 . The genealogy of the Indonesia XIX/CDC strain is shown in Figure 1 .
Blood from the primary isolation monkey (AI-4045) was passaged to A. l. griseimembra monkeys AI-4009 and AI-2627 ( Figure 1 ). Two lines (''a'' and ''b'') of the parasite were maintained. The line through AI-2627 (Line b) eventually was shown to be contaminated with Plasmodium brasilianum, suggesting a naturally acquired subpatent infection in monkey AI-2627. An attempt to ''clean'' the line via sporozoite passage through Anopheles dirus mosquitoes was unsuccessful in that monkeys AI-4003 and AI-4046 developed transient parasite densities considered too low for additional passage and study. Passage of frozen blood samples from AI-4009 to A. l. griseimembra monkey AI-4051 and S. boliviensis monkey SI-297 resulted in a P. brasilianum-free line as confirmed by microscopic examination and polymerase-chain reaction (PCR) testing.
Maximum parasite counts in Aotus and Saimiri monkeys (Table 1 ) indicated a marked variation in maximum parasitemia, a condition often encountered during early passages of human malaria parasites through splenectomized New World monkeys. Splenectomy usually removes most of any residual immunity that may be present as a result of previous infection with heterologous species of Plasmodium, and allows maximum development of subsequent parasitemia. Some animals had been previously infected with heterologous strains of P. vivax; maximum parasite counts are usually reduced in such infections.
Nine A. l. griseimembra monkeys were infected; eight had been previously infected with both P. falciparum and a heterologous strain of P. vivax. In the second passage, AI-4009 had a maximum parasite count of 2,880/L. Subsequent passage of parasitized erythrocytes to 4 monkeys (AI-2013, AI-4003, AI-4045, and AI-4046) resulted in relatively high-density maximum parasite counts between 21,600 and 37,440/ L, even though 3 of the animals had been previously in- on AI-2632 were infected for 10 consecutive days during the ascending parasitemia beginning when the parasite count exceeded 800/L and continued to a parasite count of 42,480/L. Mosquitoes fed on AI-2626 were infected on 8 consecutive days during the ascending parasitemia when the count exceeded 300/L and continued to a parasite count of 5,000/L. Three infections were induced in A. nancymai (AI-1514, AI-2168, and AI-2169). All had been previously infected with P. falciparum (AI-1514 had also been previously infected with Plasmodium simium). Maximum parasite counts were 36,000, 25,920, and 19,620/L, respectively. Mosquitoes were infected by feeding on AI-2168 on 3 different days during the ascending parasitemia 3, 4, and 6 days after reaching a parasite count Ͼ 1,000/L.
Saimiri boliviensis monkeys (Table 1 ), many of which had been used previously in studies with P. falciparum, proved to be suitable subjects for efforts to determine sensitivity to antimalarial drug treatment. All but 2 of the animals were in Line a. Two monkeys injected with parasites that had been stored frozen had either a low maximum parasite count (210/ L, 122 days after inoculation for SI-425) or a greatly extended prepatent period (66 days for SI-297). Because of efforts to determine sensitivity to drug treatment, many animals were treated prior to the expected maximum parasite count. In general, maximum parasite counts were lower than observed with infections in A. l. griseimembra monkeys. Maximum parasite counts Ͼ 10,000/L were observed in only 7 out of 27 S. boliviensis infected. Five infections were induced by the intravenous injection of sporozoites dissected from the salivary glands of Anopheles dirus mosquitoes 14 days after feeding on AI-2632. Prepatent periods were 24, 24, 29, 33, and 45 days.
Response to treatment. Thirty milligrams of chloroquine is the standard curative treatment for Aotus and Saimiri monkeys infected with sensitive strains of P. vivax. The response of this strain of P. vivax, identified as Indonesia XIX/CDC, to 10, 20, and 30 mg base of chloroquine given over 1, 2, or 3 days (Table 2) Six monkeys were treated with 30 mg of amodiaquine given over 2 days. One animal failed to clear the infection, 4 had their infections recrudesce in from 4 to 29 days, and one animal was cured.
Nine monkeys were retreated with single 10 mg doses of mefloquine after treatment failure with chloroquine or amodiaquine. The infection in one animal (SI-725) recrudesced after treatment; the remaining animals were cured of their infections. Three recrudescent infections were retreated with 20 mg mefloquine; all were cured.
DISCUSSION
New isolates of P. vivax have rarely been adapted to develop in monkeys from frozen samples, and the Indonesia XIX parasite may not be typical of most wild types of P. vivax from this area of Indonesia. However, the strain has characteristics that should be useful.
These initial studies indicate that the Indonesia XIX/CDC strain of P. vivax will develop in splenectomized Aotus and Saimiri monkeys. The strain is resistant to normally curative treatment with chloroquine and amodiaquine. The strain appears to respond adequately to treatment with mefloquine. Whether or not other treatment regimens will be effective remains to be determined.
It is anticipated that the availability of infections with such drug-resistant strains of P. vivax from monkeys will provide much needed material for the identification of molecular markers for resistance which, in turn, will help track the evolution and geographic movement of this very important human pathogen. The sporozoite transmission demonstrated to 5 splenectomized S. boliviensis monkeys indicates that this model may be suitable for the testing of causal prophylactic drugs.
